| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
 
																	D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ: CLNN) with a Buy and maintains $23 price target.
 
																	 
																	Benchmark analyst Bruce D. Jackson maintains Clene (NASDAQ:CLNN) with a Buy and lowers the price target from $33 to $31.
 
																	- SEC Filing
 
																	Novel human preclinical neuronal model for Parkinson's disease demonstrated CNM-Au8's ability to improve mitochondrial ...
 
																	D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
 
																	
 
																	Canaccord Genuity analyst Sumant Kulkarni maintains Clene (NASDAQ:CLNN) with a Buy and lowers the price target from $83 to $48.